- Home
- REGN vs TFC Comparison
REGN vs TFC Comparison
Compare REGN & TFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- TFC
- Stock Information
- Founded
- REGN 1988
- TFC 1872
- Country
- REGN United States
- TFC United States
- Employees
- REGN N/A
- TFC N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- TFC Major Banks
- Sector
- REGN Health Care
- TFC Finance
- Exchange
- REGN Nasdaq
- TFC Nasdaq
- Market Cap
- REGN 59.9B
- TFC 52.4B
- IPO Year
- REGN 1991
- TFC N/A
- Fundamental
- Price
- REGN $558.87
- TFC $42.94
- Analyst Decision
- REGN Buy
- TFC Buy
- Analyst Count
- REGN 21
- TFC 18
- Target Price
- REGN $823.86
- TFC $49.38
- AVG Volume (30 Days)
- REGN 940.4K
- TFC 8.4M
- Earning Date
- REGN 08-01-2025
- TFC 07-18-2025
- Dividend Yield
- REGN 0.63%
- TFC 4.84%
- EPS Growth
- REGN 5.03
- TFC N/A
- EPS
- REGN 39.67
- TFC 3.70
- Revenue
- REGN $14,214,200,000.00
- TFC $18,166,000,000.00
- Revenue This Year
- REGN N/A
- TFC $80.29
- Revenue Next Year
- REGN $6.65
- TFC $4.81
- P/E Ratio
- REGN $14.09
- TFC $11.59
- Revenue Growth
- REGN 5.38
- TFC 27.64
- 52 Week Low
- REGN $476.49
- TFC $33.56
- 52 Week High
- REGN $1,211.20
- TFC $49.06
- Technical
- Relative Strength Index (RSI)
- REGN 54.16
- TFC 41.91
- Support Level
- REGN $541.61
- TFC $44.82
- Resistance Level
- REGN $563.59
- TFC $46.13
- Average True Range (ATR)
- REGN 15.37
- TFC 0.93
- MACD
- REGN -0.75
- TFC -0.39
- Stochastic Oscillator
- REGN 41.57
- TFC 23.13
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About TFC Truist Financial Corporation
Based in Charlotte, North Carolina, Truist is the combination of BB&T and SunTrust. Truist is a regional bank with a presence primarily in the Southeastern United States. In addition to commercial banking, retail banking, and investment banking operations, the company operates several nonbank segments.